Trending...
- Update Any Sign Instantly with Santek EZ Sign NFC: Ultra-Slim 4-Color E-Paper Display - 681
- THINKWARE Unveils U3000 PRO: Flagship 4K/2K Dash Cam With Dual RADAR and Next-Gen Connected Services
- California Student Aid Commission Launches 2026-27 Statewide Financial Aid Cycle at Ventura College
REDWOOD CITY, Calif., June 1, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the Jeffries Virtual Healthcare Conference to be held June 2 at 1:30 p.m. ET (10:30 a.m. PT). A live webcast link of the event can be found on the Company's website at http://ir.acelrx.com/upcoming-events. Management will also be hosting one-on-one investor meetings throughout the day.
For those not available to listen to the live webcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.
More on The Californer
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.
SOURCE AcelRx Pharmaceuticals, Inc.
Related Links
www.acelrx.com
For those not available to listen to the live webcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.
More on The Californer
- Kaltra unveils reversible microchannel coils – engineered for modern heat pumps
- Phinge Announces Proposal to Combat Billions in Government Waste, Fraud, and Abuse with Proactive, Hardware-Verified Netverse App-Less Platform
- Author Calls Trump the Most Racist President in US History
- DERMA-CODE™ Announces Ingredient Transparency and Molecular Innovation in Skincare
- Michelle L Crocker releases a new book called Do Not Date An Asshole
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.
SOURCE AcelRx Pharmaceuticals, Inc.
Related Links
www.acelrx.com
Filed Under: Business
0 Comments
Latest on The Californer
- 'Wild Hermit Wellness' Has Achieved Bestseller Status in Just 2 Months Since Launch Of Organic Skincare Line
- California: Governor Newsom announces appointments 10.24.25
- Cal State LA named Pathway Champion for advancing equitable transfer pathways
- Easton & Easton, LLP Sues The Dwelling Place Anaheim and Vineyard USA for Failing to Protect Minor from Church Leaders' Sexual Abuse
- New Book "Curing Racism" Offers Hopeful Path to Healing America's Deepest Divide
- PHOTOS: Governor Newsom deploys California Volunteers, California National Guard on humanitarian mission assisting food banks as Trump's government shutdown delays SNAP benefits
- California: Governor Newsom celebrates CAL FIRE's first graduation at new Atwater training center
- Scare Safely: City of Long Beach Offers Tips for a Safe Halloween
- California: Governor's SAFE Task Force and local partners clear homeless encampments in Fresno and San Diego
- Hypnotic Hijinks of HypnoMarc Rolls into Sunnyvale for One Night Only
- California: Governor Newsom announces appointments 10.22.25
- California: Governor Newsom announces appointments 10.23.2025
- Lokal Media House Earns ServiceTitan Certified Marketer Status
- Wall Street's New Obsession? Tradewinds Aims to Revolutionize the $8B Gentlemen's Club Industry with National Peppermint Hippo™ Strategy $TRWD
- Poised for Major Growth with Strategic Military Orders, Global Expansion, and Groundbreaking Underground Mining Initiative $RMXI
- Tax Stack AI Founder Rachel Farris, Featured in Accounting Today on Solving the Accounting Pipeline
- PODS® and Cumulus Radio Announce Winner of "Imagine the PODS-ibilities" Contest
- Top Desi Indian Realtors Helping Indian Home Buyers and Sellers in Southern California
- Save the Date! Long Beach's 71st Annual Daisy Lane Parade Returns December 13
- Top Lake Elsinore, CA Realtors for First Time Home Buyers & Sellers | Lake Elsinore Real Estate